Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention

AIDS

Volumn 24, Issue 4, 2010, Pages 515-524

  Toro, Patricia L ^a   Katyal, Monica ^a   Carter, Rosalind J ^a   Myer, Landon ^a,b   El Sadr, Wafaa M ^a   Nash, Denis ^a   Abrams, Elaine J ^a  

^a Mailman School of Public Health   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Antiretroviral therapy; Developing countries; Family; HIV infections; Pregnancy; Prevention of mother to child transmission

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MORTALITY; PATIENT PARTICIPATION; PREGNANT WOMAN; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT SELECTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANT WOMEN; THAILAND; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77649240830     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283350ecd     Document Type: Article

References (56)

1. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva, Switzerland: WHO 2008.
2. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20:1391-1399.
3. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-895.
4. Dabis F, Balestre E, Braitstein P, Miotti P, Brinkhof WG, Schneider M, et al. Cohort profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005; 34:979-986.
5. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 2003; 17 (Suppl 3):S5-S15.
6. Fischer A, Karasi JC, Kibibi D, Omes C, Lambert C, Uwayitu A, et al. Antiviral efficacy and resistance in patients on antire-troviral therapy in Kigali, Rwanda: the real-life situation in 2002. HIV Med 2006; 7:64-66.
7. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, Weber JN. Comparative response of African HIV-1-in-fected individuals to highly active antiretroviral therapy. AIDS 2002; 16:1139-1146.
8. Kebba A, Atwine D, Mwebaze R, Kityo C, Nakityo R, Peter M. Therapeutic responses to AZTR3TCREFV in advanced anti-retroviral naive HIV type 1-infected Ugandan patients. AIDS Res Hum Retroviruses 2002; 18:1181-1187.
9. Landman R, Schiemann R, Thiam S, Vray M, Canestri A, Mboup S, et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS 2003; 17:1017-1022.
10. LaurentC,DiakhateN,Gueye NF, Toure MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002; 16:1363-1370.
11. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006; 42:252-259.
12. Tassie JM, Szumilin E, Calmy A, Goemaere E. Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres. AIDS 2003; 17:1995-1997.
13. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
14. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20:1163-1169.
15. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148.
16. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
17. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
18. Dalal RP, Macphail C, Mqhayi M, Wing J, Feldman C, Chersich MF, Venter WD. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008; 47:101-107.
19. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, et al. Early loss of HIV-infected patients on potent antire-troviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559-567.
20. Ginsburg A, Hoblitzelle C, Sripipatana T, Wilfert C. Provision of care following prevention of mother-to-child HIV transmission services in resource-limited settings. AIDS 2007; 21:2529-2532.
21. Gray R, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, et al. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 2005; 366:1182-1188.
22. Mataka E. Maternal health and HIV: bridging the gap. Lancet 2007; 370:1290-1291.
23. Abrams EJ, Myer L, Rosenfield A, El-Sadr WM. Prevention of mother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences. Am J Obstet Gynecol 2007; 197:S101-106.
24. Whelan D. Gender and HIV/AIDS: taking stock of research and programmes [POPLINE Document Number 165705]. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 1999. 40 p
25. WHO. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach; 2006.
26. KuhnL, Kasonde P, Sinkala M, Kankasa C, Semrau K, Vwalika C, et al. Prolonged breast-feeding and mortality up to two years postpartum among HIV-positive women in Zambia. AIDS 2005; 19:1677-1681.
27. R T-cell count. J Acquir Immune Defic Syndr 2004; 36:702-713.
28. van der Merwe K, Chersich MF, Technau K, Umurungi Y, Conradie F, Coovadia A. Integration of antiretroviral treatment within antenatal care in Gauteng Province, South Africa. J Acquir Immune Defic Syndr 2006; 43:577-581.
29. Martin F, Navaratne L, Khan W, Sarner L, Mercey D, Anderson J, et al. Pregnant women with HIV infection can expect healthy survival: three-year follow-up. J Acquir Immune Defic Syndr 2006; 43:186-192.
30. Black V, Hoffman RM, Sugar CA, Menon P, Venter F, Currier JS, Rees H. Safety and efficacy of initiating highly active anti-retroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008; 49:276-281.
31. Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R. Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS 2008; 22:1679-1681.
32. Wang B, Losina E, Stark R, Munro A, Walensky R, Wilke M, et al. Loss to follow-up in community clinics in South Africa: role of CD4 count, gender and pregnancy [poster #841]. In: 15th Conference on Retrovirus and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts, USA; 2008.
33. Rabkin M, El-Sadr WM. Saving mothers, saving families: the MTCT-Plus Initiative [case study]. Geneva, Switzerland: WHO; 2004.
34. Myer L, Rabkin M, Abrams EJ, Rosenfield A, El-Sadr WM. Focus on women: linking HIV care and treatment with reproductive health services in the MTCT-Plus Initiative. Reprod Health Matters 2005; 13:136-146.
35. WHO. Antiretroviral therapy in HIV infection in adults and adolescents: recommendations for a public health approach. Geneva, Switzerland: WHO 2006 1-128.
36. WHO. WHO list of prequalified medicinal products. Geneva, Switzerland: WHO 2007.
37. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38:963-974.
38. Tonwe-Gold B, Ekouevi DK, Viho I, Amani-Bosse C, Toure S, Coffie PA, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 2007; 4:e257.
39. Collini P, Schwab U, Sarfo S, Obeng-Baah J, Norman B, Chadwick D, et al. Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort. Clin Infect Dis 2009; 48:988-991.
40. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J 2006; 96:315-320.
41. Nash D, Katyal M, Brinkhof MW, Tuboi S, Braitstein P, Balestre E, et al. Long-term CD4 response to potent ART among ART-naive patients in several low-income countries. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts, USA; 2008.
42. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291-2302.
43. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129. (Pubitemid 34786200)
44. Egger M. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13:870-879.
45. Ross A, Van der Paal L, Lubega R, Mayanja BN, Shafer LA, Whitworth J. HIV-1 disease progression and fertility: the incidence of recognized pregnancy and pregnancy outcome in Uganda. AIDS 2004; 18:799-804.
46. R lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. The Women and Infants Transmission Study. Obstet Gynecol 1997; 89:967-974.
47. Ekouevi DK, Inwoley A, Tonwe-Gold B, Danel C, Becquet R, Viho I, et al. Variation of CD4 count and percentage during pregnancy and after delivery: implications for HAART initiation in resource-limited settings. AIDS Res Hum Retroviruses 2007; 23:1469-1474.
48. Lebon A, Bland RM, Rollins NC, Coutsoudis A, Coovadia H, Newell ML. Short communication: CD4 countsof HIV-infected pregnant women and their infected children-implications for PMTCT and treatment programmes. Trop Med Int Health 2007; 12:1472-1474.
49. Lockman S, Shapiro RL, Smeaton LM, WesterC,ThiorI,Stevens L, et al. Responsetoantiretroviraltherapy afterasingle,peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
50. Westreich D, Eron J, Behets F, Horst C, Van Rie A. Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model. J Infect Dis 2007; 195:837-846.
51. Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, Bulterys M, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007; 21:957-964.
52. Coovadia A, HuntG, Abrams EJ, ShermanG,Meyers T,Barry G, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48:462-472.
53. Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 2007; 60:724-732.
54. Moore AL, Mocroft A, Madge S, Devereux H, Wilson D, Phillips AN, Johnson M. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defic Syndr 2001; 26:159-163.
55. Boulle A, Bock P, Osler M, Cohen K, Channing L, Hilderbrand K, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678-687.
56. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, Ceffa S, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 2008; 24:555-560.